SCHEMBL6161980

SCHEMBL6161980

C#Cc1ccccc1OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.53
MAPK1 P28482 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HTR1A P08908 5/20 0.50
DRD2 P14416 1/20 0.50
LIPE Q05469 1/20 0.49
LTA4H P09960 1/20 0.47
MAPK14 Q16539 1/20 0.47
ALPG P10696 1/20 0.46
PTK2B Q14289 1/20 0.46
CCNB2 O95067 1/20 0.45
CDK1 P06493 1/20 0.45
CDK4 P11802 1/20 0.45
CCNB1 P14635 1/20 0.45
CCND1 P24385 1/20 0.45
CCNB3 Q8WWL7 1/20 0.45
ADRA1D P25100 4/20 0.44
ADRA1A P35348 4/20 0.44
ADRA1B P35368 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31139621 1.00 MAPT (0.53) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL6818008 0.83 ABCB1 (0.55) HTR1AADRA1DADRA1AADRA1BSGMS2
SCHEMBL31715924 0.83 MAOB (0.54) MAPK1L3MBTL1SGMS2HPGDGAA
Lithium SCHEMBL31715835 0.82 MAOB (0.53) MAPK1L3MBTL1SGMS2HPGDGAA
SCHEMBL448079 0.81 MAOB (0.57) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL2248786 0.81 MAPT (0.53) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL22711497 0.79 MAPT (0.43) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL339812 0.79 MAPT (0.71) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL22219370 0.78 MAPT (0.55) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL30378353 0.76 MAPT (0.45) MAPTMAPK1TDP1L3MBTL1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114907297-A Method for preparing benzodihydrofuran derivative by visible light catalysis of 2-alkynyl aryl ether and sulfonyl chloride in series 湖南警察学院 2022-08-16 CN disclosed
US-10385063-B2 Herbicidal compounds SYNGENTA PARTICIPATIONS AG (CH) 2019-08-20 US disclosed
EP-3239142-B1 CONDENSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-07-03 EP disclosed
US-9975903-B2 Condensed heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-22 US disclosed
US-20180111948-A1 HERBICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2018-04-26 US disclosed
US-20180111948-A1 HERBICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2018-04-26 US disclosed
US-20170349605-A1 CONDENSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-12-07 US disclosed
EP-3239142-A1 CONDENSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-11-01 EP disclosed
US-20050143578-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2005-06-30 US disclosed
EP-1434772-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2005-05-04 EP disclosed
US-20040192914-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2004-09-30 US disclosed
EP-1434772-A1 COMPOUNDS AND METHODS SmithKline Beecham Corporation (US) 2004-07-07 EP disclosed
WO-2003031434-A1 COMPOUNDS AND METHODS SMITH KLINE BEECHAM CORPORATION (US) 2003-04-17 WO disclosed
EP-0834499-B1 Process for the preparation of aromatic vinyl compounds DAINIPPON INK & CHEMICALS (JP) 2001-07-25 EP disclosed
EP-0834499-A1 Process for the preparation of aromatic vinyl compounds DAINIPPON INK AND CHEMICALS, INC. (JP) 1998-04-08 EP disclosed
EP-0489877-B1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 2-AMINO-6-PHENYL-4H-PYRAN-4-ONES UPJOHN CO (US) 1995-09-20 EP disclosed
US-5302613-A Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones THE UPJOHN COMPANY (US) 1994-04-12 US disclosed
US-5252735-A Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones THE UPJOHN COMPANY (US) 1993-10-12 US disclosed
EP-0489877-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 2-AMINO-6-PHENYL-4H-PYRAN-4-ONES. UPJOHN CO (US) 1992-06-17 EP disclosed
WO-1992000290-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 2-AMINO-6-PHENYL-4H-PYRAN-4-ONES THE UPJOHN COMPANY (US) 1992-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192914-A1 Compounds and methods METAP2, METAP1, DNPEP MAPT 2605/4885MAPK1 3352/4885TDP1 3624/4885
US-10385063-B2 Herbicidal compounds DDT, DAO, HPD MAPT 3777/4885MAPK1 2181/4885TDP1 1729/4885
US-20050143578-A1 Compounds and methods METAP2, METAP1, DNPEP MAPT 2341/4885MAPK1 3572/4885TDP1 4007/4885
US-20170349605-A1 CONDENSED HETEROCYCLIC COMPOUND VIP, TMPRSS15, MMP2 MAPT 4104/4885MAPK1 1254/4885TDP1 4680/4885
US-20180111948-A1 HERBICIDAL COMPOUNDS DDT, DAO, HPD MAPT 3748/4885MAPK1 2140/4885TDP1 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.